Patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) resulting from fumarate hydratase (FH) mutations may present with skin, uterine, and renal tumors, with each having unique pathologic features. This study investigated the association between prospectively identified suspicious pathology (SP) and FH mutations when patients were referred for genetic testing. METHODS: This was an institutional review board-approved cohort study of patients receiving FH testing from 2008 to 2013. SP was defined as a report of HLRCC histologic features identified during a prospective pathologic assessment. The association between SP and FH mutations was analyzed. RESULTS: FH testing was performed in 29 patients with a median age of 37 years; 15 (52%) were female, and 18 (62%) were white. Pathologists reported SP from kidney tumors (11 of 18), leiomyomas (9 of 15: uterus [n 5 8] and bladder [n 5 1]), and metastatic tumors (3 of 6) in 23 of 39 associated specimens (59%) from 21 of the 29 patients (72%). Patients with SP were younger (35 vs 51 years; P 5 .010), and those with kidney tumors more often had stage pT3 or higher renal cell carcinoma than those without SP (100% vs 33%; P 5 .006). FH mutations were present in 8 patients with SP (38%) and in 1 patient without SP (13%; P 5 .37); 7 of these patients had kidney cancer (n for SP 5 7), all with N1 disease. Analyzing SP by tissue type identified only SP from renal tumors as being significantly associated with positive testing for an FH mutation (P 5 .013). CONCLUSIONS: SP from kidney tumors was statistically associated with FH mutations. An expert pathologic assessment of renal tumors will facilitate the clinical identification of HLRCC cases, and this will result in genetic testing and targeted cancer screening for patients and at-risk family members.
INTRODUCTION
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome that results from a mutation in fumarate hydratase (FH), and patients may present with skin or uterine leiomyomas and/or and renal tumors. [1] [2] [3] Although early reports described these renal tumors as papillary renal cell carcinoma (RCC) type 2, new classifications now recognize HLRCC-associated RCC as a distinct entity. 4 Early identification of this syndrome is paramount because those with RCC often are diagnosed with advanced disease at a younger age and suffer high mortality. 5, 6 Furthermore, early identification of familial cases allows the initiation of screening strategies of proven efficacy for decreasing mortality. 7 HLRCC cases are often diagnosed by dermatologic identification of skin leiomyomas 3, 8 with or without a family history of HLRCC, and they are confirmed by testing for FH mutations. However, because of this ascertainment bias toward families affected by skin leiomyomas, 5, 8 HLRCC cases are likely to be underdiagnosed when they do not manifest as cutaneous lesions or if patients have not received a formal dermatologic evaluation in the presence of skin lesions.
Expert pathologic assessment of renal tumors may provide a unique mechanism for identifying patients with an FH mutation either with or without cutaneous lesions that may have otherwise not been diagnosed. Earlier reports have demonstrated that both renal tumor 9, 10 and leiomyoma specimens 11, 12 display unique histologic features; the hallmarks of these tumors are eosinophilic inclusion-like nucleoli with clear perinucleolar halos. The recognition of these and other characteristic morphologic features during the pathologic assessment of surgical specimens may prompt further clinical investigation, as suggested previously. 9, 10, 12 We evaluated the association between prospectively identified HLRCC suspicious pathology (SP) and the presence of FH mutations among patients referred for genetic testing for the risk of hereditary cancer.
MATERIALS AND METHODS

Study Population
In the context of an institutional review board-approved study, we identified patients who underwent clinical testing for FH mutations between 2008 and 2013. All patients were evaluated by a clinician at the Memorial Sloan Kettering Cancer Center (MSKCC) and were subsequently referred to the Clinical Genetics Service (CGS) at MSKCC. Referral by the managing clinician to CGS was made on the basis of SP findings in 21 cases, on the basis of multiple tumor types present within the same individual in 4 cases, and on the basis of clinical suspicion due to unusual pathology findings and a family history of RCC (n 5 2) or non-RCC malignancy (n 5 2) in 4 cases. Patients who were referred to CGS at MSKCC but who had genetic testing performed outside MSKCC were included if there was documentation of test results in the medical record (n 5 2). A genetic counselor and physician specialist from CGS evaluated patients and obtained consent for clinical genetic testing. We excluded tested relatives of HLRCC probands (n 5 7). Medical records of the tested patients were retrospectively reviewed for the documented presence of SP; all patients had at least 1 specimen previously reviewed by a pathologist. Pertinent clinical and pathologic data were recorded. All patients had been counseled after the results of negative and positive FH tests and provided consent for contacting family members for an evaluation after positive test results.
SP
We defined SP as a documented report of HLRCC histologic features identified during a prospective pathologic assessment. We performed a search of pathology reports signed out by an attending pathologist that specifically used the term HLRCC or hereditary leiomyomatosis and renal cell carcinoma in describing the histologic features or differential diagnosis. We specifically did not perform a retrospective pathology review for this analysis because the objective was to determine whether the pathology reports had clinical utility for informing genetic testing. Experienced attending pathologists evaluated all specimens during a routine prospective assessment, and the pathologist prospectively documented histologic findings suspicious for HLRCC when applicable; this included histologic architectural or staining patterns characteristic of HLRCC that were previously reported. 3, 9, 11, 12 Several of the tumors included in this analysis had their histology described in a previous publication, which also includes a more in-depth description of the pathologist practices for the analysis of HLRCC. 10 The tumor histology was classified by RCC subtypes according to the World Health Organization (2004) and updated International Society of Urological Pathology (2013) classification system, 13 which includes recently described subtypes such as clear cell papillary RCC. 14 We recorded corresponding tissue sites, including leiomyoma (uterus and bladder), kidney, and metastatic sites. Leiomyoma and kidney specimens were surgically removed, whereas tissues from metastatic sites were derived from percutaneous biopsies.
We performed a query of our institutional database to determine the number of patients with SP who were not evaluated by CGS at MSKCC. This query identified pathology reports with the term HLRCC or hereditary leiomyomatosis and renal cell carcinoma. We excluded 39 patients whose specimens were submitted from an outside institution for pathology review at MSKCC but who were never evaluated by an MSKCC clinician. There were an additional 27 patients with SP who had at least 1 followup visit with a clinician at MSKCC after the date of the pathology report and had not been tested for FH mutations at MSKCC: 8 patients had a follow-up visit without documentation of the SP by the clinician; 7 patients had SP documented by the clinician but had no referral to CGS; 10 patients were referred to a genetic counselor but had no documented follow-up genetic consultation; and 2 patients had documentation of an evaluation by genetic services outside MSKCC, tested positive for an FH mutation, and were included in the analysis.
Outcome and Analysis
The primary outcome of the analysis was the determination of a germline FH mutation, which confirmed a diagnosis of HLRCC. All patients underwent FH testing by a Clinical Laboratory Improvement Amendments-and New York State Department of Health-certified laboratory after appropriate genetic counseling and consent. The certified molecular genetic test for HLRCC includes a sequence analysis of the entire coding region for all patients. Clinical and pathologic variables, including the patient demographics, family medical history, presence of skin lesions, presence of uterine fibroids, history of fibroid surgery, presence of kidney tumors or metastases, and pathologic stage, grade, and histology for all specimens, were collected from medical records. We recorded whether SP was reported for each pathologic specimen. Clinical and pathologic variables for patients were annotated for all cases with and without SP with Fisher's exact test for categorical variables and with the Mann-Whitney test for continuous variables. The association between SP and FH mutations was tested for SP across all tissue types combined and for SP for each individual tissue type (kidney, leiomyoma, and metastatic sites) with Fisher's exact test. The sample size was insufficient for a multivariate analysis. The diagnostic sensitivity, specificity, negative predictive value, and positive predictive value were determined to measure the association of SP as a predictor of FH test results. The statistical analysis was performed with Stata software (version 12.0; StataCorp, College Station, Texas). A 2-sided P value < .05 was defined as significant.
RESULTS
The study cohort included 29 patients referred for primary testing of HLRCC ( Table 1 ). The median age was 37 years (interquartile range, 31-49 years); 15 (52%) were female, and 18 (62%) were white. Thirty-nine associated pathologic specimens were identified; SP was documented in 23 of the 39 specimens (59%) and in 21 of the 29 patients (72%). SP-positive specimens included kidney tumors (11 of 18), leiomyomas (9 of 15: uterus [n 5 8] and bladder [n 5 1]), and metastatic tumors (3 of 6). Only 8 of the 20 patients with kidney tumors (40%) had a histologically classifiable RCC reported; they included type 2 papillary RCC (n 5 4), papillary RCC not otherwise specified (n 5 1), clear cell RCC (n 5 1), clear cell RCC with papillary features (n 5 1), and HLRCC- related RCC (n 5 1). The remaining tumors were unclassified, although commented findings included papillary or collecting duct features. Patients with SP were younger (35 vs 51 years; P 5 .01) and those with renal tumors more often had stage pT3 or higher RCC (100% vs 33%; P 5 .006) in comparison with those without SP ( Table 2 ). The histology was classifiable for 23% of those with SP and for 71% of those without SP (P 5 .06), although 1 patient with renal tumor histology classified as HLRCC-related RCC was diagnosed with an FH mutation before nephrectomy, and the findings were consistent with this unique tumor. Previously collected specimens from this patient demonstrated uterine fibroid SP and metastatic lymph node SP, which prompted testing for an FH mutation before nephrectomy.
FH mutations were detected in 8 of 21 patients with SP (38%) and in 1 of 8 patients without SP (13%; P 5 .37). In total, 20 of 29 patients had no mutation or significant findings according to their clinical FH testing. The characteristics of all patients found to have FH mutations are shown in Table 3 , and they included 7 patients with kidney cancer (n for SP 5 7), all with N1 disease, and 2 patients with only uterine (n for SP 5 2) and skin leiomyomas (Table 3 ). All 7 patients with FH mutations and kidney cancer developed metastatic disease; they included 3 patients who died of disease 8, 11, and 47 months after nephrectomy. Mutation loci are shown in Table 3 and include the following details: 5 patients had a missense mutation, all of which were previously reported in association with HLRCC (including c.891T>A [n 5 1], c.1060G>A [n 5 2], and c.698G>A [n 5 2]). There were 2 deletions and 1 insertion for which we could not identify a previous report in association with HLRCC.
There was no significant association between SP and the FH mutation status when SP was categorized to include all tissue types (Table 4) . When it was analyzed by tissue type, SP from renal tumors was significantly associated with positive testing for an FH mutation (P 5 .013). As a predictive marker in the subset of HLRCC, renal SP had a sensitivity of 100% and a specificity of 70%. The specificity for leiomyoma SP was 30% (70% were false-positives); however, 1 case of leiomyoma SP directly led to a dermatologic diagnosis of skin leiomyomas and an FH mutation. Further genetic screening in FHpositive patients also identified 5 relatives with germline FH mutations, and they are currently being followed with imaging (data not shown). 
DISCUSSION
Patients with HLRCC may harbor clinically aggressive RCC and often present at a young age with advanced disease, 5, 6 as was true for our cohort. Moreover, many patients with FH mutations and aggressive RCC do not have cutaneous leiomyomas to aid in the diagnosis. 5 Our study demonstrates that prospective identification of special features by the pathologist and recognition by the clinician can have a substantial impact on the diagnosis of HLRCC; renal SP was significantly associated with testing positive for an FH mutation and was highly sensitive. For the subset of leiomyomas or metastatic tumors, SP was less strongly correlated with the FH mutation status. This approach to pathologic screening may promote earlier detection of FH-mutant probands and family members and provide a strategy for early detection as well as the screening of those at higher risk for inherited RCC.
Renal tumors in HLRCC patients are often described as papillary RCC type 2, 2,3,15 and some studies have retrospectively identified HLRCC cases through reports of papillary type 2 or atypical-appearing renal lesions. As mentioned previously, HLRCC-associated RCC is now recognized a distinct entity in the 2016 World Health Organization classification of renal tumors. 16 Clinicopathologic series have demonstrated a spectrum of architectural features (papillary, collecting duct, tubulocystic, sheetlike, and solid alveolar); in these reports, nucleolar findings were identified that were unique to HLRCC-related RCC. 9, 10, 17 More recent data have shown these nuclear features to be similar among uterine fibroids in HLRCC, and it has been suggested that the identification of characteristic pathologic features in uterine and renal tumors may have utility in the early detection of the syndrome. 5, 9, 12 Immunohistochemistry for 2-succinocysteine (2SC) may provide an additional role for the detection of HLRCC cases, 10, 18 although the antibody was not commercially available or routinely used at the time of diagnosis for our patients. In a related study at MSKCC, pathologists retrospectively identified a sample of HLRCC cases: 100% demonstrated diffuse and strong staining for 2SC. Among an additional 14 tumors with HLRCC-like morphologic features (10 were type 2 papillary, and 4 were unclassified), 9 were negative for 2SC, and 5 had predominantly cytoplasmic staining. 10 Raymond et al 19 reported a retrospective review of the utility of the pathologic evaluation of a renal tumor in the diagnosis of a familial case of HLRCC. A National Cancer Institute protocol for ascertaining HLRCC cases through dermatologic screening later expanded recruitment to those with kidney tumors demonstrating pathologic features characteristic of the syndrome 5 ; however, the correlation between the characteristic pathology and FH tests has not been reported.
Diagnostic features of HLRCC include uterine fibroids, renal tumors, and cutaneous leiomyomas; patients may have a family history of any of these manifestations, and the diagnosis is confirmed by tests for FH mutations.
1,2 HLRCC is most often diagnosed through the identification of cutaneous leiomyomas. 8 However, previous HLRCC series likely underestimated the true prevalence of renal tumors resulting from FH mutations; these series demonstrated an ascertainment bias due to the initial identification of families with skin leiomyomas. The prevalence of cutaneous leiomyoma has previously been reported in 50% to 100% of those with FH mutations, with very few or up to 100 lesions, and the majority of the women in these studies were affected with uterine fibroids, particularly at a young age. 1, 3, 5, 8 These studies comparatively have a much smaller proportion of RCCs (often <10%). A more recent study by Wei et al 5 demonstrated that a much higher proportion of families harboring FH mutations had RCC (62%). Our study design and cohort, derived from a large cancer center, are likely to be biased toward uterine leiomyomas and kidney tumors (7 of 9 in our series).
The findings reported here indicate that pathologic features may aid in the diagnosis when other diagnostic criteria are not observed. Although cutaneous leiomyomas are a hallmark of HLRCC, the diagnosis of these lesions often requires a dermatologic assessment, 8 and internists, urologists, or gynecologists may be less able to identify these skin lesions. One patient in our cohort had a cutaneous leiomyoma diagnosed as a result of a dermatology consultation that was prompted by a finding of SP features of a uterine leiomyoma. One reason that SP among uterine leiomyomas might be less specific for a germline FH mutation than RCC is that more than one-third of atypical leiomyomas may be FH-deficient and result from nonsyndromic inactivation or a somatic mutation. 20, 21 The current study also underscores that a family history of HLRCC may be helpful for a diagnosis, but such a history may not always be present because of patient recall or variable penetrance of the phenotype. No cases in our study had prior knowledge of family members with HLRCC, and a family history of RCC was present in 5 of 9 patients with FH mutations and in 5 of 7 patients with RCC. Other studies have documented probands with RCC with no family history of renal tumors. 22 Thus, a differential diagnosis of HLRCC suggested by SP should not be dismissed because of a lack of a family history or a lack of 1 phenotypic feature of the syndrome.
This study is limited by the small sample size, limited follow-up of patients with SP who were not tested for FH mutations, and variable patterns of referral. Complete data were not available for patients who were not tested; therefore, it is unclear whether SP patients who completed genetic testing had a higher pretest probability of an FH mutation. Regardless of a possible testing bias, we feel that the association between SP and testing positive for an FH mutation is of high clinical significance because of the lethality of the disease. Although it may be expected that expanded genomic screening of cancer-affected patients may give rise to greater detection of HLRCC as a result of anticipated or incidental genomic findings, 16 ,23 a systembased approach to the identification of pathologic features of renal tumors may constitute a directed strategy for identifying this syndrome. Further studies investigating the reproducibility of this approach across multiple centers will be required to establish the efficacy of SP as a predictive marker of HLRCC.
In conclusion, an expert pathologic determination of characteristic histologic features should trigger genetic testing for hereditary renal tumor syndromes. In this study, such expert evaluations of all tissue types were not equally associated with the presence of FH mutations. Instead, special histologic features of renal tumors demonstrated high sensitivity and were significantly associated with the FH mutation status. Clinical suspicion that includes a careful interpretation of pathologic tissues is an important pathway for identifying families with hereditary cancer syndromes and initiating targeted surveillance strategies. 
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